As companies realize the potential of Artificial Intelligence (AI) and Machine Learning (ML), applications in healthcare are expected to grow to nearly $8 billion by 2022. The biopharmaceutical industry is increasingly recognizing AI/ML’s potential to both improve decision making across R&D and commercialization, and to drive better outcomes for patients, physicians, and payers.
但是，观察者尚未看到生物制药行业中AI/ML的价值实现的有意义和持续的实现。此外，大多数内部生物制药AI/ML计划仍然分散，并且通常与主要业务分开。
In this white paper, IQVIA’s Data Science experts explore the reasons why AI/ML has had limited success in the biopharmaceutical industry to date, and contrast that examination with case studies spotlighting enterprises that successfully improved patient outcomes and streamlined internal operations through the use of AI/ML.
下载此白皮书，以发现您的生物制药组织如何通过采用AI/ML应用程序来启用当今日益复杂和竞争的环境：- 更快，更有效的临床开发
- 更精确，支持技术的商业执行
- 更好的现实世界证据提供价值
- 数据驱动的决策以降低风险
- 更有针对性的疗法可带来更好的结果